PubMed Health⌕ Search

Biomedical subjects

J Gerss

Publications and source records attributed to J Gerss.

3 recordsLinked to original sources

[Not significant--what now?].

In a statistical significance test a scientific problem is expressed by formulating a null hypothesis and an opposite alternative. Construction of an empirical decision rule usually focuses on control of the alpha-error, i.e. the probability of erroneously refusing the null hypothesis. Contrary to the alpha-error, the beta-error is not controlled and in general is of unknown size. Thus in case of a non-significant result the validity of the null hypothesis still may be highly questionable. Such an unwanted outcome of an applied test the researcher should try to avoid by choosing an appropriate study design. In case it occurs nevertheless, it is advised to further evaluate the (non-significant) result. This can be done by calculating confidence intervals of the tested effects. Furthermore the p-value can be interpreted as a metric measure of evidence against the null hypothesis. By means of a posterior power analysis the probability of a significant test result is estimated under the given circumstances. Thus possibly the applied test--under the assumption of actual validity of the alternative--turns out to have had hardly a chance of rejecting the null hypothesis. In this case the non-significant result (pointing towards the null hypothesis) is relativized substantially. On the other hand a large power points to a small probability of a beta-error.

Probability↗

Cellular and reticular variants of haemangioblastoma revisited: a clinicopathologic study of 88 cases.

The presence of histological variants of haemangioblastoma is well established, but data on the prognostic implications of histological subtyping are missing. We thus characterized clinical factors associated with histological subtypes, that is, of the cellular and reticular variant of haemangioblastoma, in a series of 88 consecutive primary haemangioblastomas of the central nervous system. Ten haemangioblastomas were classified as 'cellular' according to Cushing and Bailey. As compared to the more common 'reticular' variant (n = 78), the proportion of tumours containing glial fibrillary acidic protein-positive tumour cells (80% vs. 7%), as well as median Ki67 (MIB1) proliferation indices [4% (quartiles: 1-8%) vs. < 1% (<1-2%)], was significantly higher in cellular haemangioblastomas (P < 0.01). Recurrences were more frequent in the cellular variant [2/8 (25%) vs. 4/51 (8%)]. Kaplan-Meier analysis confirmed a significantly higher probability of recurrence in the cellular variant (Log-Rank test P < 0.01). Cox regression analysis not only confirmed the well established association of von Hippel-Lindau disease with tumour recurrence (P < 0.01), but also revealed an independent effect of histological subtype on the probability of recurrence (P < 0.05), whereas no significant influence of age, sex or tumour location was observed. To conclude, the results from this retrospective study suggest that histological subtyping of haemangioblastomas has prognostic implications and might contribute to identify patients at risk for recurrence.

Adolescent↗

Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial.

OBJECTIVE: Testosterone-containing gels have improved testosterone substitution therapy, but they are associated with the risk of interpersonal transfer. Therefore, we tested a new hydroalcoholic 2.5% testosterone gel (TGW), which was removed by washing 10 min after administration. DESIGN: The gel was applied to scrotal or non-scrotal skin in comparison to two 2.5 mg Androderm patches in a randomised, three-arm, parallel-group, controlled multicentre trial over a period of 24 weeks. We included symptomatic hypogonadal men whose morning testosterone levels were <10 nmol/l. Either 1 g TGW was applied to scrotal skin (n = 54) or 5 g to non-scrotal skin (n = 56) once daily; the patch group (n = 52) applied two patches/day. Dose titration was allowed. RESULTS: Whereas serum testosterone levels and the pre-post changes of the areas under the curve of testosterone and free testosterone between weeks 0 and 24 indicated equivalent treatment success for the patch and scrotal groups, the dermal gel group was significantly superior to the other two groups. Questionnaires on sexual function, mood and quality of life did not differ significantly between study groups, nor were prostate volume, prostate-specific antigen (PSA) levels and prostate symptoms different. However, tolerability was much better in the gel groups than the patch group. CONCLUSION: Efficacy, safety and tolerability suggest TGW as a favourable treatment for hypogonadal patients.

Administration, Cutaneous↗